Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 123INDUSTRY 71NIH 10NETWORK 10OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × carfilzomib × Clear all
NCT04813653 2025-07-24

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Tel-Aviv Sourasky Medical Center

Phase 1 Completed
3 enrolled
Plasma cell

Multiple Myeloma

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed
41 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡